Matinas BioPharma Holdings, Inc. — Cyborg Score 5/10
Mixed
Biopharmaceutical - Clinical Stage / Drug Delivery
Strategic Profile
Matinas is focused on improving the intracellular delivery of nucleic acids and small molecules with its lipid nanocrystal (LNC) platform technology. The company's focus on anti-infectives underscores its commitment to addressing areas of high unmet medical need and harnessing its expertise in reformulating established therapeutic agents for enhanced patient outcomes.
Cyborg Score Rationale
Early-stage biopharmaceutical with promising technology platform and clinical progress in anti-infectives (MAT2203 Phase III trials), but as a clinical-stage company lacks revenue and faces typical biotech development risks. Recent clinical successes demonstrate validation, but limited financial data visibility.
Top Insights
LNC platform enables oral delivery of previously IV-only medicines, reducing treatment burden and adverse events
MAT2203 (oral amphotericin B) in Phase III ORALTO trial for invasive fungal infections with compassionate use showing clinical responses
Pipeline includes MAT2501 (oral amikacin) for multidrug-resistant bacterial infections; exploring oncology applications with docetaxel
Clinical-stage company with no approved products yet; success dependent on regulatory milestones and trial outcomes
Named Competitors
Conventional amphotericin B formulations — Established IV-based antifungal products
Other oral antifungal candidates — Early-stage oral antifungal development programs
Antibiotic therapies — Conventional treatment options for bacterial infections
Recent Developments
(Mar 2024) Matinas reports completion of clinical response in three patients with invasive fusarium infection treated with MAT2203 under Compassionate Use Program
(Feb 2025) Appointment of Evelyn D'An to Board of Directors as independent director
(Jan 2025) NYSE American notification regarding minimum share price compliance
Open the full interactive Matinas BioPharma Holdings, Inc. report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.